Biotek-snakken — Maj 2024
-
Photocure : Asieris' NDA For Cevira Accepted By NMPA For Regulatory Review In China https://www.proinvestor.com/investornyt/1158788/photocure-asieris-nda-for-cevira-accepted-by-nmpa-for-regulatory-review-in-china
-
Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Calliditas Therapeutics AB
Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas Therapeutics AB (www.calliditas.se)
-
“This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN,” said Renee Aguiar-Lucander, CEO.
-
Genovis - Interim Report January – March 2024
https://mb.cision.com/Main/1712/3976051/2798815.pdf
"Best quarter for enzyme business in analytics and stronger cash position"
-
Deres PharmaShell teknologi kunne være godt bud på Long acting injectables for en række lægemidler. Har projekt med liraglutid. Desuden muligt partnerskab med Novo Nordisk, mon ikke glp1/sema, men undisclosed Her ligger upside især og Novo skal snart beslutte, om de vil indgå licensaftale. Lav marketcap., høj
risiko, stor upside.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind